OPKO Health’s BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers Jul 1, 2019
OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial Apr 12, 2019